Collaborative, innovative senior medical affairs leader with experience in building and leading highly successful cross-functional teams in the development and delivery of best-in-class, high-impact medical affairs plans. High proficiency in resource allocation and strategic planning to support project deliverables and management of large budgets.Effective influencer and strong team leader focusing on delivering impactful scientific content. Recognized for outstanding strategic thinking skills, effective communication, and collaborative leadership style. Proven track record of both building strong and turning around poorly functioning medical affairs teams. Played a key role in positively impacting the lives of hundreds of thousands of patients functioning as the medical lead for the first-in-class non-steroidal MRA for diabetic kidney disease. Innovative problem solver adept at finding solutions to challenging issues by engaging the skills of team members. Passionate about setting ambitious goals and achieving these goals through teamwork and collaboration.Areas of Expertise:Strategic Medical Affairs LeadershipClinical Trials and Scientific ExpertiseMedial Team LeaderObservation al StudiesCross-Functional Team LeadershipSelected Career Achievements:BAYER – Strategic lead for a team of 18 HQ-based medical directors and a 40-member field medical team with an annual operating budget of more than $20M. Responsible for evidence portfolio across two therapeutic indications (chronic kidney disease and heart failure) encompassing 7 active trials and studies and more than three thousand US patients. Led the development and implementation of innovative digital educational outreach campaigns for primary care physicians. NOVARTIS – Built and developed a team of 4 medical directors in 12 months to support a critical, high-visibility drug development program in rare kidney disease. Designed and launched initiatives focused on developing earlier diagnoses of rare glomerular diseases operating with a medical budget of more than $16M. Created and implemented medical education campaigns for a first-in-class complement system factor B inhibitor for rare kidney diseases. ASTRAZENECA − Spearheaded the pre-launch medical support for first-in-class HIF-PH Inhibitor for anemia of CKD. Successfully led and managed a partnership with a small, CA-based biotech in co-collaboration, aligning processes, objectives and deliverables under tight timelines and budgets. Built and developed a 3-member, high-functioning kidney team of medical directors.
Listed skills include Healthcare, Clinical Research, Medicine, Nephrology, and 9 others.
